HRD Reference Standard

Background

Homologous Recombination Repair (HRR) is one of the important ways to repair DNA double-strand damage, and the HRR pathway includes BRCA1/2 genes. Tumor cells with homologous recombination deficiency (HRD) are sensitive to platinum-containing chemotherapy and poly ADP-ribose polymerase inhibitor (PARPi).

Homologous Recombination Deficiency (HRD) has emerged as a critical biomarker for predicting therapeutic response to PARP inhibitors in various cancers. To ensure the accuracy and reproducibility of HRD testing in clinical diagnostics and research, standardized reference materials are essential. 

Key Features

• Paired immortalized cell lines

• Mimics authentic HRD-positive genomic characteristics

• including: Pathogenic BRCA1/2 variants (germline/somatic) 、Genome-wide loss of heterozygosity (LOH) 、Telomeric allelic imbalance (TAI) 、Large-scale state transitions (LST)

• Equipped with WGS data and analysis process, it can be used to verify the accuracy of the panel

• Values are determined through WGS+ double sample analysis process

• HRD score has a wide distribution range and can simulate real samples

• Standard products in the form of gDNA/FFPE/ctDNA can be customized

Applications

• Clinical assay validation for PARP inhibitor therapy selection

• Laboratory quality control for HRD score calculation algorithms

• Proficiency testing in molecular pathology workflows

• Companion diagnostic development optimization

• NGS platform performance benchmarking